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553 
REGULATING HUMAN GERMLINE MODIFICATION IN 
LIGHT OF CRISPR 
INTRODUCTION 
Scientific advancement is notorious for pushing legal and ethi-
cal boundaries, but never more so than recently. For the first 
time in history, we have the potential to not only recreate genetic 
marvels of the past, but also reshape the genetic destiny of future 
generations. This is due to the development of a new, revolution-
ary technology in genetic engineering called CRISPR—short for 
clustered regularly interspaced short palindromic repeats.
1
 
CRISPR has the potential to eradicate genes that increase a 
person‘s risk of cancer or heart disease and correct mutations for 
serious genetic diseases like cystic fibrosis, sickle-cell anemia, 
and Huntington‘s disease, to name a few.
2
 And the best part: 
CRISPR is easy to use, inexpensive, and extraordinarily effec-
tive.
3
 
Often compared to the find-and-replace function in a word-
processing program, CRISPR can correct genetic defects in whole 
organisms, as well as ensure that the changes will be passed on 
from one generation to the next (changing the organism‘s 
―germline‖).
4
 Human germline modification (―HGM‖), or deliber-
ately changing the genes in reproductive cells or embryos, is dis-
tinguishable from somatic gene editing (―gene therapy‖).
5
 Genetic 
 
 1. PAUL KNOEPFLER, GMO SAPIENS: THE LIFE-CHANGING SCIENCE OF DESIGNER 
BABIES 258 (2016) [hereinafter GMO SAPIENS]. 
 2. See Michael Specter, The Gene Hackers, THE NEW YORKER (Nov. 16, 2015), 
http://www.newyorker.com/magazine/2015/11/16/the-gene-hackers. 
 3. David Baltimore et al., A Prudent Path Forward for Genomic Engineering and 
Germline Gene Modification, 348 SCI. 36, 36–37 (2015). 
 4. See, e.g., Jon Entine, Ethical and Regulatory Reflections on CRISPR Gene Editing 
Revolution, GENETIC LITERACY PROJECT (June 25, 2015), https://www.geneticliteracypro 
ject.org/2015/06/25/ethical-and-regulatory-reflections-on-crispr-gene-editing-revolution/ 
(―It‘s akin to a biological word processing system that allows scientists to cut and paste 
DNA almost as easily as if they were editing a journal article.‖). 
 5. See ASS‘N OF REPROD. HEALTH PROF‘LS, HUMAN CLONING AND GENETIC 
MODIFICATION: THE BASIC SCIENCE YOU NEED TO KNOW 5, [hereinafter ARHP, HUMAN 
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alterations in reproductive cells and embryos affect more than 
just an individual consenting patient—they become part of the 
resulting child‘s genetic make-up.
6
 This creates the potential to 
introduce changes that will echo through future gene pools and 
alter the legacy of human diversity. 
Between forced sterilization laws in the 1920s and Nazi eugen-
ics experiments during World War II, the United States and other 
countries already have a sordid history of trying to ―improve‖ the 
human race via heritable genetic modification.
7
 Thus, some are 
concerned history will repeat itself if current regulations do not 
evolve to confront this revolutionary advancement. 
CRISPR advocates are enthusiastic about its promise for cor-
recting mutations for serious genetic diseases.
8
 Some proponents 
go so far as to say that bioethics should simply ―[g]et out of the 
way,‖ and that ―slowing down research has a massive human 
cost.‖
9
 To these optimists, society should ―cure‖ as many people as 
possible, as soon as possible, and should focus on the ethical is-
sues as they arise. However, even scientists that support the use 
of CRISPR as a gene-editing tool agree that its potential to alter 
the legacy of human diversity has progressed much faster than 
society‘s ability to deliberate its social implications and permissi-
ble uses.
10
 These more moderate proponents say that pausing to 
apply a moral imagination to the future does not kill research or 
its potential applications.
11
 
While opponents of CRISPR technology advise banning it for 
the foreseeable future, some argue that anything short of a com-
plete and total ban is insufficient.
12
 The reason for such strong 
 
CLONING] http://www.arhp.org/upload Docs/cloning.pdf. 
 6. See id. 
 7. See generally ADAM COHEN, IMBECILES: THE SUPREME COURT, AMERICAN 
EUGENICS, AND THE STERILIZATION OF CARRIE BUCK 251–83 (2016) (discussing the history 
of eugenics in the United States). 
 8. See, e.g., Steven Pinker, Opinion, The Moral Imperative for Bioethics, BOS. GLOBE 
(Aug. 1, 2015), https://www.bostonglobe.com/opinion/2015/07/31/the-moral-imperative-for-
bioethics/JmEkoyzlTAu9oQV76JrK9N/story.html (arguing against bioethicists ―bog[ging] 
down research‖ because of the positive implications of CRISPR). 
 9. Id. 
 10. See Edward Lanphier et al., Don’t Edit the Human Germ Line, 519 NATURE 410, 
410–11 (2015). 
 11. See id. 
 12. See Sarah Karlin, Gene Editing: The Next Frontier in America’s Abortion Wars, 
POLITICO (Feb. 16, 2016, 5:21 AM), http://www.politico.com/story/2016/02/gene-editing-
abortion-wars-219230. 
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opposition is twofold: some feel human beings should never be the 
subject of experimentation, regardless of their stage in life; others 
see the potential for ―designer babies‖ and worry the technology 
will result in social inequality.
13
 
This comment evaluates the United States‘ current regulatory 
scheme as it applies to CRISPR and related gene-modifying tech-
nologies and discusses the ethical ramifications of regulating hu-
man germline modification versus continuing to allow self-
regulation within the scientific community. Part I explains what 
CRISPR is, how it works, and its impact on genetic engineering 
technology. Although CRISPR offers ―unparalleled potential for 
modifying [both] human and nonhuman genomes,‖
14
 this comment 
focuses primarily on the use of CRISPR technology to manipulate 
the human germline.
15
 Part II discusses the social and bioethical 
implications of altering the human germline, including safety 
concerns, multigenerational consequences, equity issues, and eth-
ical complications involved with editing human embryos. Part III 
examines the United States‘ current regulatory scheme as it ap-
plies to gene-modifying technologies, discusses the need for re-
form in light of CRISPR germline-editing therapies, looks at sev-
eral possible solutions to improve the existing scheme, and 
proposes an adapted regulatory framework.  
I.  WHAT IS HUMAN GERMLINE MODIFICATION? 
HGM means deliberately changing the genes that are trans-
mitted to future generations by modifying DNA in eggs, sperm, or 
very early embryos.
16
 Germline modification is distinguishable 
from somatic gene editing because genetic alterations in repro-
ductive cells and embryos are heritable and affect more than just 
an individual consenting patient—they affect every cell in the 
body and become part of the resulting child‘s genetic make-up.
17
 
 
 13. See id. 
 14. Baltimore et al., supra note 3, at 36.  
 15. Hongbao Ma & Guozhong Chen, Gene Transfer Technique, 3 NATURE & SCI. 25, 25 
(2005). (―Gene transfer can be targeted to somatic (body) or germ (egg and sperm) cells. In 
somatic gene transfer the recipient‘s genome is changed, but the change will not be passed 
on to the next generation. In germline gene transfer, the parents‘ egg and sperm cells are 
changed with the goal of passing on the changes to their offspring.‖).  
 16. ARHP HUMAN CLONING, supra note 5, at 5.  
 17. Id. (defining somatic genetic engineering as ―genetic engineering that targets the 
genes in specific organs and tissues of the body of a single existing person without affect-
ing genes in their eggs or sperm‖). 
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Thus, unlike somatic genetic modification, HGM has the potential 
to introduce changes that will echo through future gene pools and 
―alter the legacy of human diversity.‖
18
 
Until recently, most research and clinical resources have been 
directed toward developing somatic gene therapy techniques.
19
 
But inheritable genetic modifications are preferable to non-
heritable alterations for several reasons, such as to prevent the 
inheritance of fatal genetic diseases or avoid having to repeat so-
matic therapy generation after generation.
20
 Moreover, HGM of-
fers the long-term benefit of decreasing the prevalence of certain 
inherited diseases that currently plague the human gene pool.
21
 
Because somatic gene therapy treats only the affected individual, 
it could not produce the same long-term effect of reducing the in-
cidence of genetic diseases.
22
 
Another alternative to HGM is pre-implantation genetic diag-
nosis (―PGD‖), which can be used to detect genetic abnormalities 
prior to pregnancy.
23
 PGD works as follows: 
Couples at risk for having a child with a chromosomal or genetic dis-
ease undertake IVF to permit embryo screening before transfer, ob-
viating the need for later prenatal diagnosis and possible abortion. A 
dozen or more eggs are fertilized and the embryos are grown to the 
four-cell or the eight-to-ten-cell stage. One or two of the embryonic 
cells (blastomeres) are removed for chromosomal analysis and genet-
ic testing. Using a technique called polymerase chain reaction to am-
plify the tiny amount of DNA in the blastomere, researchers are able 
to detect the presence of genes responsible for one or more genetic 
disorders. Only the embryos free of the genetic or chromosomal de-
terminants for the disorders under scrutiny are made eligible for 
transfer to the woman to initiate a pregnancy.
24
 
PGD was developed as a way for parents to have children free 
of severe or fatal genetic disorders without having an abortion.
25
 
 
 18. Editorial, Future-Proofing, 528 NATURE 164, 164 (2015). 
 19. See MARK S. FRANKEL & AUDREY R. CHAPMAN, AM. ASS‘N FOR THE ADVANCEMENT 
OF SCI., HUMAN INHERITABLE GENETIC MODIFICATIONS 1 (2000), http://www.aaas.org/sites 
/default/files/migrate/uploads/germline.pdf. 
 20. Id. at 3. 
 21. Id.  
 22. Id.  
 23. See THE PRESIDENT‘S COUNCIL ON BIOETHICS , BEYOND THERAPY: BIOTECHNOLOGY 
AND THE PURSUIT OF HAPPINESS 38 (2003) [hereinafter BEYOND THERAPY], http://www. 
vanderbilt.edu/olli/files/Beyond-Therapy-Kass.pdf. 
 24. Id. at 38–39.  
 25. See Susannah Baruch, Preimplantation Genetic Diagnosis and Parental Prefer-
ences: Beyond Deadly Disease, 8 HOUSING J. HEALTH L. & POL‘Y 245, 245–46 (2008) (indi-
cating PDG was initially created as an ―alternative to prenatal genetic diagnosis and ter-
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However, there are certain situations in which genetic screening 
and embryo selection are not effective for this purpose.
26
 For ex-
ample, if both parents have the same genetic mutation—meaning 
100% of their offspring are guaranteed to have that same disor-
der—then PGD would be useless because there are no mutation-
free embryos from which to choose.
27
 Another example is where 
only one parent carries the genetic disorder, but there are so few 
embryos that PGD is unable or unlikely to find one lacking a mu-
tation.
28
 HGM, on the other hand, offers the potential to complete-
ly eradicate the genetic mutation from this homozygous couple‘s 
germline, thereby giving them the opportunity to have a biologi-
cally related child that does not suffer from the disorder.
29
 
In the same way that HGM has the potential to produce lasting 
benefits, it also has the potential to produce lasting physical, so-
cial, and ethical consequences. Despite the advent of CRISPR, 
there are still important technical obstacles to inheritable genetic 
applications.
30
 The technology in its current form is not error-free; 
 
mination‖). 
 26. Id. at 250. 
 27. See Eric S. Lander, Brave New Genome, 373 NEW ENG. J. MED. 5, 6 (2015) (indi-
cating that while there are roughly 3600 rare monogenic disorders—or disorders caused by 
single-gene defects, which would be the easiest to correct with CRISPR technology—cases 
where one parent is homozygous for a dominant disorder or both parents are homozygous 
for a recessive disorder are very rare).  
For dominant Huntington‘s disease, for example, the total number of homo-
zygous patients in the medical literature is measured in dozens. For most re-
cessive disorders, cases are so infrequent (1 per 10,000 to 1 per million) that 
marriages between two affected persons will hardly ever occur unless the two 
are brought together by the disorder itself. The most common situation would 
probably be two parents with recessive deafness due to the same gene (among 
the many that can cause inherited deafness) who wish to have a hearing 
child. 
Id.  
 28. See GMO SAPIENS, supra note 1, at 243 (discussing couples dealing with infertility 
or genetic problems including mitochondrial disorders). 
 29. See FRANKEL & CHAPMAN, supra note 19, at 3. For example, this may be necessary 
in a situation where both parents have sickle cell anemia because 100% of their offspring 
will be afflicted with the disease. Henry I. Miller, Letter to the Editor, Germline Gene 
Therapy: We’re Ready, 348 SCI. 1325, 1325 (2015). Alternative techniques such as pre-
implantation genetic diagnosis would be inadequate in this situation because the purpose 
of genetic screening is to select embryos that do not carry the condition. See FRANKEL & 
CHAPMAN, supra note 19, at 3. Thus, the only way for this couple to have a biological child 
that does not also have sickle cell anemia would be to genetically modify the child‘s 
germline prior to ex vivo. 
 30. FRANKEL & CHAPMAN, supra note 19, at 3. 
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and even if it were, successful germline intervention would still 
pose the risk of unknown multigenerational side effects.
31
 
A. Explanation of CRISPR Technology 
1.  How CRISPR Works 
CRISPRs are genomic elements in bacteria that provide im-
munity against future viral infection.
32
 Essentially, it is a bacteri-
al defense mechanism that operates as a ―genetic sandwich.‖
33
 Af-
ter being infected by a virus, the bacteria ―remember‖ it by 
sandwiching remnants of viral genes between odd, repeated bac-
teria DNA sequences—these are the ―clustered regularly inter-
spaced short palindromic repeats‖ from which the CRISPR name 
is derived.
34
 These sequences are then stored in the bacterial ge-
nome, which enable a bacterium and its ancestors to more easily 
defend themselves using an enzyme, typically Cas9, if infected by 
the same virus in the future.
35
 
Upon discovering this immune response in bacteria, research-
ers began programming CRISPR for use in other organisms by 
simply replacing the viral DNA that is sandwiched between 
CRISPR sequences with the DNA of other cell types, including 
that of humans.
36
 The entire process is actually very simple and is 
accomplished by the interaction of two elements. First, research-
ers program CRISPR by matching a ―guide‖ molecule with a spe-
cific DNA sequence and aligning the molecule against a precise 
position on the DNA double helix where editing is required.
37
 
Once deployed, these serve as a road map for CRISPR to reach its 
 
 31. See infra text accompanying note 107.  
 32. GMO SAPIENS, supra note 1, at 12. 
 33. See Carl Zimmer, Breakthrough DNA Editor Born of Bacteria, QUANTA MAG. (Feb. 
6, 2015), https://www.quantamagazine.org/20150206-crispr-dna-editor-bacteria/. 
 34. John Travis, Making the Cut, 350 SCI. 1456, 1457 (2015); see also Zimmer, supra 
note 33 (indicating bacteria use Cas9 enzymes to grab fragments of viral DNA then chop it 
in two, preventing the virus from replicating). 
 35. GMO SAPIENS, supra note 1, at 12 (―Much the same way as the police have a data-
base of the ‗fingerprints‘ of criminals, CRISPR elements act as a store of viral fingerprints 
that generations of bacteria keep and use to mount rapid immune responses to viral infec-
tions.‖). 
 36. Id. at 12–13; see also Zimmer, supra note 33 (indicating scientists successfully cut 
out a particular piece of DNA in human cells and replaced it with another one in January 
2013). 
 37. See Amy Maxmen, The Genesis Engine, WIRED (Aug. 2015), http://www.wired.com/ 
2015/07/crispr-dna-editing-2/. 
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intended target.
38
 Once there, CRISPR cuts and splices both 
strands of the DNA double helix with an enzyme, typically Cas9, 
in order to remove the sequence from the genome.
39
 
2.  Current and Future Uses for CRISPR Technology 
Researchers have already used CRISPR in a variety of settings, 
most of which have nothing to do with germline modification. 
Some examples include: making blight-resistant wheat crops;
40
 
prolonging the life of tomatoes by turning off genes that control 
how quickly they ripen;
41
 altering the genes in pigs so they could, 
in theory, ―grow human organs for transplant;‖
42
 repairing defec-
tive DNA in mice and curing them of genetic disorders;
43
 knocking 
out every gene in a cancer-cell line to identify every one of the 
cell‘s ―Achilles‘ heels,‖ which should make it ―possible to build a 
comprehensive road map for [every type of specific] cancer‖;
44
 and 
permanently inactivating HIV in patient‘s blood cells, which 
could potentially cure AIDS.
45
 
In the germline modification setting, CRISPR has already been 
used successfully to modify germ cells, non-reproductive cells, and 
both human and primate embryos.
46
 While CRISPR‘s use in modi-
fying human embryos was limited to those that were non-viable, 
 
 38. See id. 
 39. See id. 
 40. See Kristen V. Brown, Inside the Garage Labs of DIY Gene Hackers, Whose Hobby 
May Terrify You, FUSION (Mar. 29, 2016, 7:00 AM), http://fusion.net/story/285454/diy-cris 
pr-biohackers-garage-labs/. 
 41. See Specter, supra note 2 (explaining this approach is distinguishable from using 
genetically modified organisms—or ―GMOs‖—to enhance food crops because GMOs require 
the introduction of foreign DNA into foods, whereas CRISPR may be achieved by the dele-
tion of certain genes out of foods). 
 42. Brown, supra note 40. 
 43. Zimmer, supra note 33. 
 44. Specter, supra note 2 (indicating ―every cancer is a specific, personal disease‖ and 
that, until CRISPR, the wide genetic variations in cancer cells made it difficult to effec-
tively develop treatments). 
 45. See Rafal Kaminski et al., Elimination of HIV-1 Genomes from Human T-
Lymphoid Cells by CRISPR/Cas9 Gene Editing, 6 SCI. REP. 1, 1–2 (Mar. 4, 2016), http:// 
www.nature.com/articles/srep22555. 
 46. Jennifer Doudna, Perspective: Embryo Editing Needs Scrutiny, 528 NATURE S6 
(2015); see Yuyu Niu et al., Generation of Gene-Modified Cynomolgus Monkey via 
Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos, 156 CELL 836, 839 (2014) (us-
ing cynomologus monkey embryos); see also Puping Liang et al., CRISPR/Cas9-Mediated 
Gene Editing in Human Tripronuclear Zygotes, 6 PROTEIN & CELL 363, 363–64 (2015) 
(modifying nonviable human embryos). 
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the fact that the technology could be used to genetically modify 
human embryos prompted an international summit comprised of 
leading doctors and biomedical researchers in December 2015.
47
 
The purpose of the summit was to discuss the safety and ethical 
implications of human gene editing and to confront a newly plau-
sible prospect: altering the human germline to correct genetic 
diseases, versus altering it to offer ―enhancements.‖
48
 
Some of CRISPR‘s futuristic uses include creating glowing 
plants and reviving the woolly mammoth: the former has already 
been accomplished;
49
 the latter is still a work-in-progress.
50
 Other 
more chilling possibilities include the use of CRISPR to create 
bioweapons,
51
 conjure ―invasive mutant[]‖ species,
52
 ―catalyze spe-
cific genetic changes in an entire population or environmental 
system,‖
53
 or develop ―designer babies‖ for enhancement purposes, 
rather than to correct genetic abnormalities.
54
 
II. CRISPR‘S IMPACT ON GENETIC ENGINEERING TECHNOLOGY 
The importance of CRISPR technology in the realm of biomedi-
cal technology ―cannot be overstated.‖
55
 ―CRISPR has already rev-
olutionized basic research by allowing scientists to readily modify 
the genome of cells and model organisms, enabling the develop-
ment of an expanding set of tools to understand fundamental bio-
logical questions.‖
56
  
This section proceeds in three parts. First, in order to fully ap-
preciate CRISPR‘s impact on genetic engineering technology, it 
 
 47. John Travis, Making the Cut, 350 SCI. 1456, 1456 (2015). 
 48. Id.  
 49. See Brown, supra note 40. 
 50. See Zimmer, supra note 33 (indicating scientists are trying to ―rewrite the ge-
nomes of elephants, with the ultimate goal of re-creating a woolly mammoth‖). But see 
GMO SAPIENS, supra note 1, at 69 (admitting de-extinction is a ―fun idea,‖ but warning of 
the potential risks, including the subtle increase in public acceptance of cloning, specifical-
ly, human cloning). 
 51. GMO SAPIENS, supra note 1, at 196. 
 52. Maxmen, supra note 37.  
 53. GMO SAPIENS, supra note 1, at 191 (referring to this hypothetical large-scale ge-
netic process as ―gene drive‖). 
 54. See generally id. (discussing the effects of the CRISPR-Cas9 technology on the 
possibility of ―designer babies‖).  
 55. Ante S. Lundberg & Rodger Novak, CRISPR-Cas Gene Editing to Cure Serious 
Diseases: Treat the Patient, Not the Germ Line, 15 AM. J. BIOETHICS 38, 38 (2015). 
 56. Id. 
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sets the stage by reciting the accolades received and critical ac-
claim prompted by CRISPR‘s discovery. It next explains the dis-
tinguishing features that make CRISPR worthy of such honor 
and reception. Finally, it describes the ways in which the very 
features that make CRISPR so revolutionary are also cause for 
serious concern. 
A. Accolades 
Although it is not the first of its kind, given its revolutionary 
nature and international recognition, it is no surprise that 
CRISPR and the researchers responsible for its development have 
already received numerous accolades. CRISPR was named Sci-
ence magazine‘s 2015 Breakthrough of the Year,
57
 has been de-
scribed by MIT Technology Review as ―the [b]iggest [b]iotech 
[d]iscovery of the [c]entury,‖
58
 and is expected to ―change medicine 
forever.‖
59
 In addition, CRISPR‘s cofounders, Jennifer Doudna 
and Emmanuelle Charpentier, have received several prominent 
honors and awards for their collaborative discovery
60
—including 
the 2016 L‘Oréal-UNESCO for Women in Science award,
61
 the 
Princess of Asturias Award for Technical and Scientific Re-
search,
62
 and Time magazine‘s list of 100 Most Influential People 
 
 57. Travis, supra note 47, at 1456–57 (proclaiming CRISPR promises to do everything 
from wiping out diseases to creating super crops and that ―it‘s only slightly hyperbolic to 
say that if scientists can dream of a genetic manipulation, CRISPR can now make it hap-
pen‖). 
 58. Antonio Regalado, Who Owns the Biggest Biotech Discovery of the Century?, MIT 
TECH. REV. (Dec. 4, 2014), https://www.technologyreview.com/s/532796/who-owns-the-
biggest-biotech-discovery-of-the-century/. 
 59. Zimmer, supra note 33, reprinted in The Biggest Biotech Discovery of the Century 
is About to Change Medicine Forever, BUS. INSIDER (Feb. 18, 2015, 4:44 PM), http://www. 
businessinsider.com/the-biggest-biotech-discovery-of-the-century-is-about-to-change-medi 
cine-forever-2015-2; see also Press Release, Gairdner Found., 2016 Canada Gairdner 
Awards Honour CRISPR-Cas Researchers and HIV/AIDS Leaders (Mar. 23, 2016) [herein-
after 2016 Gairdner Awards] (announcing that the winners of all five 2016 Canada Gaird-
ner International Awards were scientists who played a significant role in the discovery 
and development of CRISPR technology). 
 60. For a complete list of honors and awards, see Jennifer A. Doudna, Curriculum Vi-
tae [hereinafter Doudna, CV], https://biosciences.lbl.gov/wp-content/uploads/2015/10/Doud 
na_cv_082815-CURRENT. pdf (last visited Dec. 16, 2016) and Emmanuelle Charpentier, 
Curriculum Vitae, http://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV_Charpen 
tier_Emmanuelle_EN.pdf (last visited Dec. 16, 2016). 
 61. Honoring Women Scientists Who Are Changing the World, UNESCO, [hereinafter 
Honoring Women Scientists] http://en.unesco.org/news/honoring-women-scientists-who-
are-changing-world (last visited Dec. 16, 2016).  
 62. Doudna, CV, supra note 60; see also Lourdes Riquelme, CRISPR Technology Re-
ceives the Spanish ‘Nobel Prize’, LABIOTECH.EU (June 1, 2015), http://labiotech.eu/crispr-
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in the world, to name a few.
63
 There have also been ―whispers‖ of 
a possible Nobel prize in CRISPR‘s future.
64
 
B. Distinguishing Features 
So what makes CRISPR worthy of being called this century‘s 
biggest discovery in biotechnology? One reason is that nature, not 
science, is at the heart of this gene-editing tool.
65
 But aside from 
being a product of Mother Nature, CRISPR has three features 
that distinguish it from other methods of gene editing and make 
it the most revolutionary technique on the market today: (1) sim-
plicity, (2) accuracy, and (3) affordability. 
1.  Simplicity 
First, CRISPR makes the complex work of editing the human 
genome relatively easy. Previous technologies using molecules 
known as zinc finger nucleases (―ZFNs‖) and transcriptional acti-
vator-like effector nucleases (―TALENs‖) also precisely alter cho-
sen DNA sequences,
66
 and are currently used in clinical trials.
67
 
 
technology-receives-the-spanish-nobel-prize/ (calling the Princess of Asturias Award the 
―Spanish equivalent to the Nobel prize‖). 
 63. Mary-Claire King, Emmanuelle Charpentier & Jennifer Doudna, TIME (Apr. 16, 
2015) http://time.com/3822554/emmanuelle-charpentier-jennifer-doudna-2015-time-100/; 
see also 2016 Gairdner Awards, supra note 59 (naming Doudna and Charpentier as two of 
the five scientists chosen to receive Canada Gairdner International Awards). 
 64. See, e.g., John Travis, Inside the Summit on Human Gene Editing: A Reporter’s 
Notebook, SCI. MAG. (Dec. 4, 2015, 3:45 PM), http://www.sciencemag.org/news/2015/12/in 
side-summit-human-gene-editing-reporter-s-notebook (saying a Nobel prize is ―widely ex-
pected‖ for the scientists that discovered this new DNA-changing technology); Philip 
Hemme, CRISPR Patent War to End After the Discovery of a New Editing Protein Other 
Than Cas9?, LABIOTECH.EU (Sept. 30, 2015), http://labiotech.eu/crispr-patent-war-end-
discovery-new-editing-protein-cas9/ (predicting in 2015 that Doudna and Charpentier 
were ―short-listed to receive the next [N]obel prize‖); Joe Palca, In Hopes of Fixing Faulty 
Genes, One Scientist Starts with the Basics, NPR (Oct. 13, 2014, 3:20 AM), http://npr.org 
/sections/health-shots/2014/10/13/354934248/in-hopes-of-fixing-faulty-genes-one-scientist-
starts-with-the-basics. But see Dani Bancroft, Sorry CRISPR, You’ll Have to Wait Another 
Year to Win a Nobel Prize!, LABIOTECH.EU (July 10, 2015), http://labiotech.eu/sorry-crispr-
youll-have-to-wait-another-year-to-win-a-nobel-prize/ (stating even though CRISPR is 
―[b]iotech history in the making‖ and ―one of the most talked about gene-editing tools‖ in 
the industry, Doudna and Charpentier surprisingly did not win the 2015 Nobel Prize in 
Chemistry); Sarah Buhr, CRISPR Loses Nobel to Tiny Machines, TECHCRUNCH (Oct. 5, 
2016), https://techcrunch.com/2016/10/05/crispr-loses-nobel-to-tiny-machines/ (calling it 
―quite a shock‖ that CRISPR did not receive a Nobel prize, yet again, in 2016).  
 65. See Zimmer, supra note 33. 
 66. Travis, supra note 47, at 1456. 
 67. STEVEN OLSON, INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: A GLOBAL 
DISCUSSION 3 (2015) [hereinafter OLSON, INTERNATIONAL SUMMIT]. 
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However, these gene targeting technologies are much more cum-
bersome and difficult to use than their CRISPR counterpart.
68
 
A side-by-side comparison reveals that, while all three are 
highly specific and efficient, CRISPR is the only technique that is 
easily constructed and able to edit multiple sites simultaneous-
ly.
69
 First, CRISPR offers a one-component target design system, 
which is easy for researchers to construct.
70
 This enables re-
searchers to easily target a gene by replacing its complementary 
nucleotide sequence, which will modify the new target gene.
71
 
This feature ―not only simplifies the experimental design, it also 
yields equal or greater guiding efficiency.‖
72
 Second, CRISPR is 
capable of introducing multiple gene disruptions simultaneous-
ly.
73
 This feature allows researchers to edit multiple genes in a 
single organism with only one transformation, avoiding the need 
to complete several time-consuming screening procedures.
74
 Given 
these deficiencies, CRISPR appears to be the superior gene-
editing technology, as well as the most user friendly.
75
 
The simplicity with which CRISPR allows researchers and stu-
dents to change genomes has furthered countless experiments 
that were ―previously difficult or impossible to conduct.‖
76
 Beyond 
being difficult to perform, prior methods of gene editing were very 
long and drawn-out in two respects. First, depending on the or-
ganism, the process of editing a gene, much less a genome, often 
took scientists several months to perform.
77
 Second, even after 
 
 68. Id. ZFNs are accurate and effective, but expensive and difficult to engineer. See 
Heidi Ledford, CRISPR, The Disruptor, 522 NATURE 20, 21 (2015); see also infra text ac-
companying note 90 (comparing the cost of ZNFs to that of CRISPR). Thus, ZFN technolo-
gy was never widely adopted. Ledford, supra at 21. TALENs are more similar to CRISPR 
technology; however, like ZFNs, they are also fairly complicated and expensive. See Max-
men, supra note 37. 
 69. Jin-Song Xiong et. al, Genome-Editing Technologies and their Potential Applica-
tion in Horticultural Crop Breeding, 2 HORTICULTURE RES. 2, 7 tbl.2 (2015). 
 70. See Martin Jinek et al., A Programmable Dual-RNA–Guided DNA Endonuclease 
in Adaptive Bacterial Immunity, 337 SCI. 816, 820 (2012). 
 71. Xiong et al., supra note 69, at 5.  
 72. CRISPR Cas9-gRNA Design, APPLIED BIOLOGICAL MATERIALS, https://www.abm 
good.com/marketing/knowledge_base/CRISPR_Cas9_gRNA_Design.php (last visited Dec. 
16, 2016). 
 73. Xiong et al., supra note 69, at 5.  
 74. Id. 
 75. See GMO SAPIENS, supra note 1, at 12; see also Ledford, supra note 68, at 21 
(―CRISPR methodology is quickly eclipsing zinc finger nucleases and other editing tools.‖). 
 76. Doudna, supra note 46, at S6. 
 77. See Alex Buckley, CRISPR-Cas9: Harbinger of Human Gene Editing and Its Ethi-
cal Turmoil, FRONTIERS MAG. (Nov. 5, 2015), http://frontiersmag.wustl.edu/2015/11/05/cri 
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scientists completed the editing process, it would often take an-
other few months for the experiment to reach maturity.
78
 
To put this into perspective, in the past, a researcher studying 
the effects of a specific gene in mice models would have to intro-
duce, or ―knock out,‖
79
 a specific gene into a blastocyst,
80
 insert the 
blastocyst into a female uterus, wait several months for the fe-
male to produce offspring, wait for the resulting offspring to suffi-
ciently age and, only then, could the researcher study the gene‘s 
effect.
81
 In contrast, with CRISPR technology, a researcher per-
forming the same experiment no longer has to wait six months for 
the mice to breed in order to study the gene. Instead, scientists 
can use CRISPR to directly edit a mouse‘s genome and study the 
side effects in a matter of weeks.
82
 
Scientists and researchers are not alone in reaping the benefits 
of this easy-to-use gene-editing technology. CRISPR has also cat-
alyzed a movement of ―DIY scientists‖ hoping to try their hand at 
modifying genes in plants, animals, and perhaps even one day, 
humans.
83
 While it may be too soon to predict garage labs of DIY 
babies, CRISPR starter kits have already hit the market and now 
offer a wide range of potential products and uses.
84
 
 
spr-cas9-harbinger-of-human-gene-editing-and-its-ethical-turmoil/ (indicating that, with 
CRISPR, ―researchers no longer have to wait six months for their mice to breed,‖ but can 
―directly edit the animals‘ genomes in mere weeks‖). 
 78. See id. 
 79. Kyle Davis, CRISPR Probes the Inner Workings of the Genome in Real Time, NAT‘L 
HUM. GENOME RES. INST. (May 8, 2015), https://www.genome.gov/27560763 (indicating 
that, unlike early techniques, CRISPR enables a gene to be ―knocked out‖ while the mouse 
is alive, which decreases the longevity of experiments). 
 80. See FRANKEL & CHAPMAN, supra note 19, at 59 (defining a blastocyst as ―[a] pre-
implantation embryo consisting of 30–150 cells‖). 
 81. See Buckley, supra note 77. 
 82. See id. 
 83. See, e.g., Brown, supra note 40 (explaining how ―a 30-year-old Mississippi resident 
who never attended college, first started doing at-home experiments after seeing [CRISPR] 
kits to make glowing plants . . . online.‖). 
 84. See, e.g., DIY Yeast CRISPR Kit, ODIN, http://www.the-odin.com/diy-bacterial-
gene-engineering-crispr-kit/ (last visited Dec. 16, 2016) (offering a CRISPR starter kit for 
$160 that edits the ADE2 gene to give it a red pigment); GLOWING PLANT, http://www. 
glowing plant.com/maker (last visited Dec. 16, 2016) (selling glowing plants for $100, glow-
ing plant seeds for $40, and a DIY glowing plant maker kit for $300); see also Loz Blain, 
Do-It-Yourself CRISPR Genome Editing Kits Bring Genetic Engineering to Your Kitchen 
Bench, NEW ATLAS (Nov. 11, 2015), http://www.newatlas.com/home-crispr-gene-editing-kit 
/40362/ (indicating it costs only $130 to ―have a crack at re-engineering bacteria so that it 
can survive on a food it normally wouldn‘t be able to handle,‖ and $160 to ―get your eukar-
yote on and edit the ADE2 gene of yeast to give it a red pigment‖). 
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2. Accuracy 
Second, in addition to being a user-friendly tool, CRISPR is 
able to modify DNA sequences in living organisms with unprece-
dented precision.
85
 
CRISPR-Cas9 can pinpoint important but tiny gene sequences in our 
vast genomes, the genetic equivalent of finding a needle in a hay-
stack. Once there, it can erase and/or change A‘s, C‘s, G‘s, or T‘s, or 
even larger genomic regions, in surprisingly precise ways. CRISPR 
can literally re-write the genomic book inside of us.
86
 
Traditional gene-editing techniques worked more like a ―hatch-
et than [a] scalpel‖ and were rarely precise.
87
 Though the devel-
opment of ZFNs and TALENs did provide a more enhanced form 
of genome editing than traditional methods, CRISPR will make 
this process even faster, easier, and more accurate than ever be-
fore.
88
 
3.  Affordability 
Third, CRISPR has made the gene editing process not only 
simple and reliable, but also much more affordable.
89
 ―Customized 
Zinc finger and TALENs systems can cost anywhere around 
~$5000 or ~$500 respectively, while a CRISPR/Cas9 system can 
cost as little as $30.‖
90
 These price differences can be attributed to 
a variety of factors. One reason is that ZFNs are very difficult to 
construct in ordinary research labs, so they are typically designed 
by commercial sources and, thus, expensive.
91
 Although TALENs 
cost less than ZFNs, they are more difficult to deliver efficiently 
due to their large size.
92
 Another reason the TALEN system is 
 
 85. OLSON, INTERNATIONAL SUMMIT, supra note 67, at 1. 
 86. GMO SAPIENS, supra note 1, at 11–12. 
 87. See Specter, supra note 2 (attributing the imprecision of earlier gene-editing tech-
nologies to the fact that ―they could recognize only short stretches within the vast universe 
of the human genome‖). 
 88. Id. 
 89. See id. 
 90. Nathan Guo, CRISPR—The Future of Synthetic Biology, LUX CAP. (July 7, 2015) 
http://www.luxcapital.com/news/crispr/; see also Ledford, supra note 68, at 21 (―Research-
ers often need to order only the RNA fragment; the other components can be bought off the 
shelf. Total cost: as little as $30.‖). 
 91. CTR. FOR MOUSE GENOMICS, GENOME ENGINEERING WITH ZFNS, TALENS AND 
CRISPR/CAS9, http://www.ucalgary.ca/mousegenomics/files/mousegenomics/introduction-
to-engineered-nucleases.pdf (last visited Dec. 16, 2016); Ledford, supra note 68, at 21 
(stating ZFNs typically start at $5000 or more to order.) 
 92. See Jeffrey M. Perkel, Genome Editing with CRISPRs, TALENs and ZFNs, 
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more expensive than CRISPR is because TALENs are more time 
consuming to construct, which requires additional labor costs.
93
 
C. Concerns 
The development of CRISPR technology represents an unprec-
edented advancement in germline engineering and holds great 
promise for next generation therapeutics; however, it has sparked 
an ethical firestorm. Now that CRISPR has been used to modify 
nonviable human embryos
94
 and to create a generation of gene-
modified primates that are physiologically similar to humans,
95
 it 
is only a matter of time before HGM clinical trials will be pur-
sued. This raises numerous challenges across the spectrum, from 
research to implementation.  
Several scientists have expressed both safety and ethical con-
cerns associated with CRISPR technology—specifically, the po-
tential for exploiting non-therapeutic modification, off-target ge-
nome modifications, and the existence of viable alternatives, such 
as in vitro genetic profiling and screening.
96
 Other major concerns 
include unequal access to CRISPR germline technology (if and 
when it reaches the distribution phase), the potential for eugen-
ics, whether the costs outweigh the expected benefits, and ―moral 
grayness inherent to genetic modification of human life.‖
97
  
This comment addresses many of these concerns. Part III pro-
poses a regulatory framework with specific policies that conscien-
tiously phase the use of CRISPR technology in HGM at a pace re-
sponsive to ethical examination.  
 
BIOCOMPARE (Aug. 27, 2013), http://www.biocompare.com/Editorial-Articles/144186-Gen 
ome-Editing-with-CRISPRs-TALENs-and-ZFNs/ (―Labs can build custom TALENs for a 
fraction of what ZFNs cost. Addgene sells individual TALEN plasmids for $65 apiece, and 
complete kits for a few hundred dollars. Dan Voytas‘ popular Golden Gate TALEN 2.0 kit 
costs $425.‖). 
 93. See A. A. Nemudryi et al., TALEN and CRISPR/Cas Genome Editing Systems: 
Tools of Discovery, 6 ACTA NATURAE 19, 36 (2014). 
 94. See generally Liang et al., supra note 46 (discussing CRISPR gene editing in non-
viable human embryos). 
 95. See Yuyu Niu et al., supra note 46, at 836–37 (indicating researchers selected 
cynomologus monkey as the model because of their similarities to humans). 
 96. See, e.g., Baltimore et al., supra note 3, at 37; Edward F. Lanphier et al., supra 
note 10, at 410–11; see also GMO SAPIENS, supra note 1, at 260 (defining off-target effect 
as an errant edit by CRISPR). 
 97. Niklaus H. Evitt et al., Human Germline CRISPR-Cas Modification: Toward a 
Regulatory Framework, 15 AM. J. BIOETHICS 25, 25 (2015). 
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While advocates and skeptics of CRISPR technology put forth a 
wide range of social and ethical arguments, many of these issues 
are beyond the scope of this comment, including parental auton-
omy, constitutional reproductive issues, cloning, gender selection, 
and abortion. Instead, three social and bioethical issues are dis-
cussed. The first addresses concerns about CRISPR‘s ease of use 
and wide spread availability. This concern sparked the recent de-
bate concerning CRISPR technology, and it is the primary reason 
many scientists and bioethicists are calling for regulation of 
HGM. The second focuses on the technical issues associated with 
using CRISPR technology to perform HGM. The third addresses 
ethical concerns of HGM. 
1.  Ease of Use and Widespread Accessibility 
Last year, Nature Biotechnology asked a group of scientists 
whether they thought HGM was inevitable; many of them re-
sponded yes.
98
 Why? Because CRISPR technology is widely used, 
easy to repeat, and makes the possibility of germline editing 
―more accessible to a wider range of individuals.‖
99
 While there 
are still challenges on both the technical and biological fronts, 
―the rapid development and widespread adoption of [this] simple, 
inexpensive, and remarkably effective genome engineering meth-
od‖ is catalyzing the conversation about how HGM should be 
managed and regulated.
100
 
2.  Underdeveloped Safety Mechanisms 
CRISPR is still far from ready to modify the human germline,
101
 
but that may not stop over-ambitious scientists who are anxious 
to get in on the CRISPR revolution. In its current form, CRISPR 
poses several safety concerns, namely off-target effects, unex-
 
 98. See Katrine S. Bosley et al., Supplementary Comments, CRISPR Germline Engi-
neering—The Community Speaks, 33 NATURE BIOTECH. 478–86 (2015), http://www.nature. 
com/nbt/journal/v33/n5/extref/nbt.3227-S1.pdf (providing the unedited responses of Bosley 
and colleagues and showing that far more scientists think germline modification is inevi-
table than represented in the edited published version) [hereinafter Supplementary Com-
ments]. 
 99. Id.  
 100. Baltimore et al., supra note 3, at 36–37. 
 101. Lander, supra note 3, at 6; see also Maxmen, supra note 37 (―Engineered humans 
are a ways off—but nobody thinks they‘re science fiction anymore.‖). 
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pected multigenerational side effects, and a lack of a validated 
reversal mechanism.
102
 
Researchers in China recently applied the technique to a non-
viable human embryo in an attempt to correct a disorder that in-
terferes with the ability to make healthy red blood cells.
103
 How-
ever, their efforts were largely unsuccessful.
104
 The study 
demonstrated that CRISPR was much less accurate in targeting 
genes in embryos than it is in isolated cells and highlighted that 
―much remains to be learned regarding the efficiency and specific-
ity of CRISPR/Cas9-mediated gene editing in human cells, espe-
cially in embryos.‖
105
 However, this ―failure‖ is unlikely to dis-
courage others from trying CRISPR again in the HGM setting. 
After all, that is the purpose of experimentation—the failure of 
one is simply a learning experience for another. 
Even with enhanced accuracy, the practice will not likely be 
risk-free.
106
 The CRISPR technique could be completely perfected 
and still lead to unexpected multigenerational side effects that go 
unnoticed for several years.
107
 For example, a genetic variant that 
decreases the risk of one disease could increase the risk of anoth-
er.
108
 Unless these effects are studied closely over time and 
against a diverse backdrop, the full medical implications of many 
genetic variants will not be fully understood until they present 
themselves in fully developed human subjects.
109
 In the end, even 
in a hypothetical future scenario with an essentially perfectly ac-
curate gene-editing technology, ―opting for PGD is going to be the 
wiser choice for parents and doctors almost every time.‖
110
 ―The 
reality of PGD as a competing and generally superior technology 
to human genetic modification needs further discussion.‖
111
 
 
 102. See Evitt et al., supra note 97, at 28. 
 103. See Liang et al., supra note 46, at 363–64; Maxmen, supra note 37. 
 104. See Maxmen, supra note 37. 
 105. Liang et al., supra note 46, at 364; see also Maxmen, supra note 37. 
 106. Lander, supra note 27, at 6. 
 107. See Evitt et al., supra note 97, at 28. 
 108. See Lander, supra note 27, at 6 (―[T]he CCR5 mutations that protect against HIV 
also elevate the risk for West Nile virus, and multiple genes have variants with opposing 
effects on risk for type 1 diabetes and Crohn‘s disease.‖). 
 109. See id. at 6–7.  
 110. GMO SAPIENS, supra note 1, at 123; see also BEYOND THERAPY, supra note 23, at 
41 (discussing various uses for pre-implantation genetic diagnosis).  
 111. GMO SAPIENS, supra note 1, at 123. 
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In addition to posing unknown multigenerational risks, the 
CRISPR method also currently lacks a validated reversal meth-
od.
112
 Meaning, if the process is used and does result in unintend-
ed side effects, there would be no way to undo the modifications. 
This issue further complicates an already controversial matter 
because, even if the resulting side effects are not necessarily dan-
gerous (or even negative), there is something intrinsically wrong 
with modifying the genetic disposition of a person‘s lineage and 
not providing a companion reversal mechanism for future genera-
tions to utilize if they so choose.
113
 
3.  Ethical Dilemmas 
CRISPR‘s potential to alter the genetic destiny of generations 
to come is both exciting and dangerous. Thus, the arguments on 
both sides of the controversial public debate surrounding the use 
of CRISPR to modify the human germline are as fervent as to be 
expected. On the one hand, if we can eradicate devastating dis-
eases such as sickle cell anemia, should we not? If the basic tech-
nology is already in place, there may come a time when it is mor-
ally justifiable, even obligatory, to use CRISPR to modify a 
defective germline that poses an imminent threat to afflicted in-
dividuals.
114
 On the other hand, just because we can fix so-called 
―defective‖ genes, does that necessarily mean that we should? 
Having the basic technology already in place may not actually be 
a good thing if it can be easily manipulated for unethical purposes 
or pose danger to the resulting child. This concerns human be-
ings, after all—real-life, walking, talking, breathing people who 
will forever feel the repercussions of the decisions we make today 
concerning their biological fate. 
This part addresses four ethical dilemmas related to CRISPR 
germline modification. The first issue concerns the stigmas and 
inequalities that the use of CRISPR technology in the HGM set-
ting could create or exacerbate. The second dilemma confronts the 
potential economic pressures to undergo HGM procedures, as well 
as issues related to consumer demand for HGM products and ser-
vices. The third concerns how all of these factors—social stigma, 
inequality, economic pressure, and consumer demand—could re-
 
 112. See Evitt et al., supra note 97, at 26. 
 113. See id. 
 114. See GMO SAPIENS, supra note 1, at 99. 
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sult in what is known as ―positive‖ eugenics. The fourth issue re-
lates to embryonic research and development. 
a.  Reinforcing Stigmas and Exacerbating Inequalities 
Social justice considerations demand that discrimination and 
oppression be addressed when it comes to preventing disease and 
promoting health. ―[T]he line between diversity and disability is 
fuzzy.‖
115
 By treating certain conditions as disabilities that need to 
be ―fixed‖ via biomedical interventions like HGMs, biomedical re-
searchers may overlook, and unintentionally reinforce, stigmas 
and social disparities.
116
 In addition, ―[t]he association of racial, 
ethnic, and other groups with particular diseases could lead to 
new forms of stigmatization.‖
117
 The use of gene-editing tech-
niques is sown with economic and social values and interests that 
could easily reproduce existing hierarchies without careful scru-
tiny.
118
 
Science that is intended to benefit society can ―unintentionally 
reproduce social injustices—for example, in the way that ge-
nomics has inadvertently reinforced certain racial categories.‖
119
 
For this reason, it is vitally important to include diverse perspec-
tives of actors outside the medical field (such as policy makers 
and historians) in order to ensure that ―assessments of risks and 
benefits are not limited to medical risks alone.‖
120
 As HGM tech-
nology ―becomes more widespread, it will serve to further stigma-
tize the disabled and promote the notion that some lives are not 
worth living or are better off prevented in the first place.‖
121
 Un-
 
 115. OLSON, INTERNATIONAL SUMMIT, supra note 67, at 4. 
 116. Id. 
 117. Id. 
 118. Id. 
 119. Id. 
 120. Id. 
 121. PRESIDENT‘S COUNCIL ON BIOETHICS, REPRODUCTION AND RESPONSIBILITY: THE 
REGULATION OF NEW BIOTECHNOLOGIES 97 (2004) [hereinafter REPRODUCTION AND 
RESPONSIBILITY], https://repository.library.georgetown.edu/bitstream/handle/10822/55938 
1/_pcbe_final_reproduction_and_responsibility.pdf?sequence=1&isAllowed=y. Frankel and 
Chapman argue HGM may lead to increased prejudice against persons with disabilities 
―as long as Americans still discriminate unfairly on the basis of physical appearance, an-
cestry, or abilities.‖ FRANKEL & CHAPMAN, supra note 19, at 38. They argue that in a coun-
try like the United States,  
which has a long and disturbing history of drawing sharp distinctions among 
citizens on the basis of race and ethnicity and where many persons harbor be-
liefs in biological determinism. It is important to remember [that] past at-
tempts to use reproductive interventions to improve the genetic prospects of 
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less covered by insurance or subsidized by taxpayers, widespread 
use of HGM could also expand the gap between the ―haves‖ and 
the ―have-nots‖ in society.
122
 
b.  Economic Pressures and Consumer Demand 
―[T]he private sector has strong commercial motivations to de-
velop both treatments for disease and procedures to enhance hu-
man traits.‖
123
 This is, in part, due to the 1980 Supreme Court de-
cision Diamond v. Chakrabarty, which allowed genetically 
modified organisms (―GMOs‖) to be characterized as intellectual 
property and, therefore, be owned.
124
 This decision ―opened the 
door to the patenting of almost any GMO,‖ thereby setting the 
stage for private companies to pursue gene-editing technology as 
a strong source of potential new income.
125
 
―This momentum for GMOs was further bolstered by the U.S. 
FDA‘s approval two years later in 1982 of the first human GMO 
product: insulin made from GM bacteria that had been designed 
in a laboratory to produce large amounts of the drug.‖
126
 
While genetically modified humans would not be patentable, 
GM techniques for making modified people likely would be.
127
 
These methods—more specifically, those focused on curing or 
treating human disease—are where the long-term financial gain 
of CRISPR will ultimately lie.
128
 If achieved, economic forces to 
reduce health care costs could put pressure on people to change 
the genetic sequences associated with disease. ―The association of 
 
future generations [ultimately] reinforced and exacerbated social injustices 
against the poorer, less powerful, and more stigmatized [members of society].  
Id. 
 122. FRANKEL & CHAPMAN, supra note 19, at 37. 
 123. OLSON, INTERNATIONAL SUMMIT, supra note 67, at 3. 
 124. See 447 U.S. 303, 310 (1980) (finding that a genetically modified bacterial strain is 
patentable); see also GMO SAPIENS, supra note 1, at 33, 35. 
 125. GMO SAPIENS, supra note 1, at 35. 
 126. Id. 
 127. See id. (indicating patents for technologies that could, in the future, be used in the 
process of making GM humans are pending and that some have already been awarded, 
including Professor Feng Zhang‘s CRISPR-Cas9 patent, which is currently disputed by 
CRISPR co-founder Jennifer Doudna). But see Stephanie M. Lee, Jennifer Doudna Has 
Won a CRISPR Gene-Editing Patent, BUZZFEED (Feb. 16, 2016, 5:15 PM), https://www. 
buzzfeed.com/stephaniemlee/new-crispr-patent?utm_term=.faAJ9wAg2v#.jkMR4rBnay 
(stating that Doudna was recently awarded a patent encompassing a much wider range of 
CRISPR uses, but that the patent dispute with Zhang is still ongoing). 
 128. See Maxmen, supra note 37. 
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racial, ethnic, and other groups with particular diseases could 
lead to new forms of stigmatization,‖ while ―[t]he belief that genes 
influence particular behaviors or other complex traits could lead 
to pressures to change those genes in future generations.‖
129
 
Similarly, patients with genetic diseases have a strong drive to 
find cures for those diseases, and their ardor should not be un-
derestimated. Many of these patients would be interested in 
HGM if it were to become clinically available.
130
 Perhaps, more 
concerning than the desperate patient is the concerned parent. 
While they may have good intentions, one cannot reasonably ex-
pect future parents to resist the slew of pharmaceutical market-
ing campaigns promoting the use of HGM for improvement pur-
poses, rather than for medical necessity, that would occur if 
CRISPR technology became widely available to consumers at an 
affordable price. By nature, parents are fundamentally predis-
posed to want the very best for their children.
131
 As a result, many 
parents might not be able to distinguish between appropriate in-
tervention and unnecessary enhancement: 
[M]ost of us parents want our children to be healthy and happy. One 
could view basic parenting efforts as a form of ―enhancement‖ over 
the grim alternative of putting your child at risk of malnutrition and 
such. However, common sense dictates that doing things such as 
feeding our child a healthy diet and taking care of one‘s own health 
as a mother during pregnancy are entirely different than genetically 
enhancing your child by heritably altering her or his DNA in every 
cell of their body.
132
 
Thus, parents‘ desire to nurture, protect, and see their off-
spring thrive could translate into consumer demand for particular 
attributes and could lead people to pursue options for human 
gene editing in the private sector.
133
 And while doing so would be 
within their rights as parents, the fact that it would be difficult to 
regulate under the current regulatory scheme could pose serious 
concerns as to the safety and validity of such procedures.
134
 
 
 129. OLSON, INTERNATIONAL SUMMIT, supra note 67, at 4. 
 130. Id. at 3. 
 131. See FRANKEL & CHAPMAN, supra note 19, at 40. 
 132. GMO SAPIENS, supra note 1, at 171–72. 
 133. See OLSON, INTERNATIONAL SUMMIT, supra note 67, at 4. 
 134. See id. 
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c.  ―Positive‖ Eugenics 
Working in combination with one another, the above factors 
could lead to what is known as ―positive‖ eugenics. If certain ge-
netic characteristics are perceived to be of a lesser quality than 
others, that stigma, combined with economic pressures from in-
terested third parties—such as insurance companies or drug 
manufacturers—could lead to greater support for genetic human 
enhancement for the purpose of making people ―better,‖ even 
where there is no medical necessity.
135
 While it is a far cry from 
the forced sterilization or controlled breeding America experi-
enced in the 1960s, this type of thinking could cause people to as-
sociate human ―quality‖ with genetics and make potential parents 
feel morally obligated to utilize HGM technology—as if doing oth-
erwise would be a disservice to their unborn child and genera-
tions to come.
136
 
While the selection of gametes through sperm banks and oocyte 
donation with the intention of making better babies—an already 
widespread practice that is largely accepted by society—is argua-
bly a form of eugenics, it is notably different than using technolo-
gy to proactively alter the human germline. On the most extreme 
end of the spectrum, the technology has the potential to alter the 
genetic destiny of the human race in a single generation.
137
 On the 
more realistic end of the spectrum, HGM could ―lead to decreased 
diversity in our species and to more discrimination against cer-
tain classes of people.‖
138
 
 
 135. See GMO SAPIENS, supra note 1, at 173, 176. 
 136. See id. at 172–73 (quoting fertility innovator and eugenicist Robert Edwards who 
stated, ―[s]oon it will be a sin of parents to have a child that carries the heavy burden of 
genetic disease. We are entering a world where we have to consider the quality of our chil-
dren.‖). 
 137. Paul Knoepfler touches on this by comparing it to dog breeding. Id. at 178. Eugen-
icist Julian Savulescu says, ―what works for dog breeding should work for humans as well, 
except hugely accelerated by genetic technology. . . . What took us ten thousand years in 
the case of dogs could take us a single generation through genetic selection of embryos.‖ 
Id. at 178. Similarly, Professor Gregory Pence argues that ―[m]any people love their re-
trievers and their sunny dispositions around children and adults. . . . Would it be so terri-
ble to allow parents to at least aim for a certain type, in the same way that great breed-
ers . . . try to match a breed of dog to the needs of a family?‖ Id. Knoepfler calls these dog-
human trait modification analogies ―disturbing‖ and Professor Pence‘s idea of creating 
―sunny‖ children via genetics particularly ―creepy.‖ Id. 
 138. Id. at 180 (suggesting parents have an obligation to avoid letting racism, sexism, 
and other forms of discrimination influence reproductive choices). 
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Further, even if HGM does not result in a superior class of hu-
man beings, there is still likely to be an equity problem in terms 
of access to HGM technologies on both a national and interna-
tional scale.
139
 On a national scale, for example, if and when 
CRISPR technology becomes operable in human beings, treating 
or curing sickle-cell anemia would indeed be one of its most com-
pelling uses.
140
 But because sickle-cell anemia affects primarily 
black communities,
141
 and because only about one in four blacks 
have health insurance,
142
 the very class of people that would bene-
fit from the technology would be unlikely to create a huge de-
mand absent state intervention and assistance. Similarly, on the 
international front, ―Nigeria is very interested in human gene ed-
iting, given that it has the highest number of sickle cell cases in 
the world.‖
143
 However, the country would not likely be able to 
take advantage of the technology unless it improved its clinical 
and research capacity.
144
 If not properly controlled, CRISPR and 
other cutting-edge gene-editing technologies have the potential to 
empower this new, more powerful form of ―positive‖ eugenics, and 
pose major social risks, such as deepening the socioeconomic di-
vide and creating new genetic divisions amongst classes and 
countries.
145
 
d. Human Embryo Experimentation 
Research involving HGM in human embryos has the potential 
to provide invaluable information about gene editing and lead to 
major discoveries concerning fertility and early human develop-
ment.
146
 Therefore, rather than be prohibited, such research 
 
 139. See OLSON, INTERNATIONAL SUMMIT, supra note 67, at 5. 
 140. See Miller, supra note 29, at 1325 (recalling a ―20-year-old patient with sickle cell 
anemia who had suffered three strokes, been crippled by hemorrhages into his major 
joints, and was in unrelenting pain from the arthritis that resulted‖ and thus arguing that 
we ―need to push the frontiers of medicine to rid families of [such] monstrous genetic dis-
eases.‖). 
 141. Who Is at Risk for Sickle Cell Disease?, NAT‘L HEART, LUNG & BLOOD INST., (Aug. 
2, 2016), https://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk. 
 142. CTRS. FOR DISEASE CONTROL & PREVENTION, SUMMARY HEALTH STATISTICS: 
NATIONAL HEALTH INTERVIEW SURVEY (2014), http://ftp.cdc.gov/pub/Health_Statistics/NC 
HS/NHIS/SHS/2014_SHS_Table_P-11.pdf. 
 143. OLSON, INTERNATIONAL SUMMIT, supra note 67, at 5. 
 144. Id. 
 145. See GMO SAPIENS, supra note 1, at 173–74, 176, 180.  
 146. See id. at 239. 
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―should only be conducted under certain very limited and strictly 
controlled conditions.‖
147
 
―To optimize gene-editing tools for clinical use in human em-
bryos intended to produce babies, you are likely to need to ‗prac-
tice‘ on thousands of embryos to perfect the methodology.‖
148
 This 
prompts serious moral and ethical considerations.
149
 ―[E]mbryos 
bear an intermediate moral status between nonhuman life and a 
fetus.‖
150
 Thus, both ―researchers and future parents have an obli-
gation to respect the moral[] . . . status of the human embryo.‖
151
 
There is a strong argument, however, that HGM fails to meet this 
obligation because it ―either renders the embryo morally neutral 
or diminishes it to the status of property or goods.‖
152
 
III.  RECOMMENDATIONS 
The development of CRISPR technology represents a revolu-
tionary advancement in genetic engineering: it is simple to use, 
inexpensive, highly accessible, and has proven to be remarkably 
effective in a variety of genomic settings.
153
 However, this com-
ment suggests that these features—the very characteristics that 
make CRISPR such a revolution in biotechnology—also pose nu-
merous safety and ethical concerns to modern society.
154
 And 
while the technology has not yet reached a point at which it can 
be safely used to modify the human genome, in light of the rapid 
advancements to date, it would be wise to begin implementing a 
mechanism of oversight.
155
 
 
 147. Id. at 239–40 (stating editing work involving human embryos should be only done 
in a laboratory setting). 
 148. Id. at 160 (indicating these tests may be done with no intention to use the embry-
os to produce babies). 
 149. See, e.g., id. at 160 (―Is that ethical? And where do you get all those human eggs 
and embryos?‖). 
 150. Evitt et al., supra note 97, at 26; see also REPRODUCTION AND RESPONSIBILITY, su-
pra note 121, at 111 (indicating embryos are not considered ―human subject[s],‖ and thus 
fall outside FDA oversight and protection until and unless they are implanted in vivo). 
 151. OLSON, INTERNATIONAL SUMMIT, supra note 67, at 4. 
 152. Id.  
 153. See Baltimore et al., supra note 3, at 36. 
 154. See supra Part II.C (identifying the negative implications related to CRISPR‘s 
ease of use and widespread accessibility, explaining the risks of using CRISPR technology 
in its current form, and discussing four major ethical dilemmas posed by the use of 
CRISPR in HGM). 
 155. Baltimore et al., supra note 3, at 37. 
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This part proceeds in two sections. First, it discusses deficien-
cies with current regulation.
156
 It then proposes an expanded reg-
ulatory framework that addresses the social and bioethical con-
cerns discussed throughout this comment. 
A. Lack of Existing Regulation 
At present, there are no federal laws or regulations governing 
human germline modification.
157
 However, the Dickey-Wicker 
Amendment (D-W) prevents federal funding of research involving 
the destruction of human embryos
158
 and there is extensive feder-
al regulation of research involving somatic gene therapy.
159
 This 
aperture in applicable regulation is likely attributable to the fact 
that, until recently, HGM has been merely speculative.
160
 While 
the idea of altering the genetic makeup of a human being has 
been theoretically possible for some time, it has also been highly 
impractical given the technical barriers, monetary cost, and its 
controversial nature.
161
 CRISPR has changed all of that. HGM is 
not only on the table, it is now considered inevitable by many sci-
entists due to the advent of CRISPR technology.
162
 Those who be-
lieve HGM is evitable base their rationale on human decision-
making: ―When it comes to germ-line engineering, we are masters 
of our own destiny. The sun rising and setting every day is inevi-
table. Germ-line engineering is a choice we have the opportunity 
to make.‖
163
 
The scientific community has done well to confront the implica-
tions of CRISPR early and head-on. Researchers from around the 
world have met to discuss the potential and formidable uses of 
CRISPR, held workshops to produce a consensus report on the 
 
 156. These ideas were adapted from Girard Kelly, Comment, Choosing the Genetics of 
Our Children: Options for Framing Public Policy, 30 SANTA CLARA TECH. L.J. 303 (2014). 
 157. See REPRODUCTION AND RESPONSIBILITY, supra note 121, at 110. But see GMO 
SAPIENS, supra note 1, at 96 (indicating some states—including Michigan, Minnesota, and 
Pennsylvania—prohibit research on embryos if it leads to their destruction). 
 158. The Balanced Budget Downpayment Act, Pub. L. No. 104-99, § 128, 110 Stat. 34 
(1996); see GMO SAPIENS, supra note 1, at 96.  
 159. See REPRODUCTION AND RESPONSIBILITY, supra note 121, at 110. 
 160. See id. at 168. 
 161. See Bosley et al., supra note 98. Qi Zhou and Jinsong Li discuss the technical and 
ethical barriers surrounding HGM. Id. 
 162. See id. Researchers, ethicists, and business leaders tend to agree on its inevitabil-
ity. Id. 
 163. Id.  
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ethical and policy issues of gene transfer, and collaborated with 
major scientific journals to publish articles that encourage re-
searchers to ―slow down, ask difficult questions beyond the sci-
ence, and make[] conscious and well-considered decision[s].‖
164
 
However, the current laissez-faire approach to regulation is based 
largely on the notion that health professionals are better suited to 
make crucial judgment calls on a case-by-case basis, as they have 
specialized expertise and are more ―familiar with the details and 
circumstances involved.‖
165
 But because CRISPR has the potential 
to be used outside just the medical profession, encouragement 
will likely not go far before enforcement will need to step in. 
At present, the National Institute of Health (―NIH‖) and the 
Food and Drug Administration (―FDA‖) are two main federal bod-
ies overseeing gene-transfer research. The NIH oversees the fed-
eral funding of gene-transfer research through its Recombinant 
DNA Advisory Committee (―RAC‖), while the FDA regulates 
gene-transfer clinical trials and products.
166
 In their current form, 
these authorities would fail to adequately regulate the use of 
CRISPR for HGM purposes due to the following limitations: First, 
FDA oversight is limited to gene-therapy products and research 
protocols involving ―human subject[s].‖ Therefore, experimenta-
tion on human embryos and gametes fall outside the FDA‘s pur-
view.
167
 Second, oversight by RAC is limited to projects and insti-
tutions that receive NIH funding.
168
 Thus, privately funded exper-
iments fall outside the RAC‘s purview. The following sections 
separately address these limitations. 
1. Food and Drug Administration (FDA) 
The FDA is responsible for ensuring the safety and effective-
ness of all gene-transfer therapy products and research proto-
cols.
169
 Gene-therapy products mean biologically based articles—
which are those removed from a human subject, modified outside 
the body, and then reintroduced back into the same human sub-
ject—as well as new articles, either natural or synthetic, that are 
 
 164. Id.  
 165. REPRODUCTION AND RESPONSIBILITY, supra note 121, at 8–9 (implying that the 
practice of medicine occupies a special place in the American legislative and legal system). 
 166. Id. at 110–11. 
 167. See id. at 111. 
 168. Id. 
 169. Id. at 110–11. 
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transferred to the human subject for the purpose of genetically al-
tering the subject‘s cells.
170
 Research protocols that fall within the 
purview of the FDA include any transfers in which new genetic 
material is introduced into a human subject to replace missing or 
flawed DNA, for the purpose of treating or curing a disease.
171
 
This type of gene-transfer is considered a ―clinical trial‖ and re-
quires prior approval from the FDA.
172
 
While the FDA has broad authority to regulate all research and 
products related to somatic gene editing, the legal situation re-
garding the use of CRISPR technology to modify the human ge-
nome is less clear.
173
 Technically, the FDA has no general authori-
ty to regulate research and products related to HGM because 
gametes and embryos are not ―human subjects.‖
174
 This effectively 
allows for experimentation on any human embryos as long as 
they are not thereafter placed in utero or ―aimed at the develop-
ment of a ‗product‘ subject to its approval.‖
175
 
If and when technology becomes safe enough to use in utero at 
the clinical development phase, the FDA would have the authori-
ty to regulate claims of safety and effectiveness of germline ther-
apy products—but probably not the products themselves.
176
 Be-
cause human subject protections only reach embryos once they 
are implanted through in vitro fertilization (―IVF‖), FDA regula-
tions may not legally apply to early embryos or gametes that are 
not considered legal subjects.
177
 However, if the regulations did 
apply, the FDA would not likely approve HGM technologies at 
this time, as CRISPR has not been proven entirely safe or effec-
tive in editing the human genome. 
 
 170. Id. at 111. 
 171. Id. 
 172. Id. (indicating an investigational new drug (IND) application must be submitted 
to the FDA prior to any gene-transfer clinical trial). 
 173. See GMO SAPIENS, supra note 1, at 95. 
 174. REPRODUCTION AND RESPONSIBILITY, supra note 121, at 111 (indicating embryos 
are not considered ―human subjects,‖ and thus do not receive all the attendant protections 
of the Common Rule and FDA safeguards until they are implanted in vivo). 
 175. Id. at 131. 
 176. See id. at 54–55. 
 177. See supra note 174 and accompanying text; see also REPRODUCTION AND 
RESPONSIBILITY, supra note 121, at 113 (explaining that the FDA has no ―clear legal au-
thority to consider the safety of future generations‖). The Office of Human Research Pro-
tections (OHRP) and the FDA under the Common Rule protect embryos outside a woman‘s 
uterus as human subjects for the purpose of research on pregnant women and fetuses. See 
id. at 131–32, 135. 
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2.  National Institute of Health (NIH) 
The NIH provides oversight of gene-transfer technologies and 
funding.
178
 Compared to the FDA, the NIH ―provides more limited 
oversight through its Recombinant DNA Advisory Committee.‖
179
 
The RAC considers the ―ethical implications of—and offers advice 
to the NIH director about—novel gene-transfer research proto-
cols‖ that involve introducing genes into human subjects and are 
connected to NIH funding.
180
 While the NIH is responsible for 
overseeing some gene-transfer research studies, its oversight and 
review is limited to the projects and institutions it funds.
181
 
Currently, the RAC‘s decision not to consider HGM studies 
that aim to produce modified children effectively prevents fund-
ing for any such work.
182
 However, this moratorium on federally 
funded gene editing is simply a policy not to ―entertain proposals 
for germ line alterations,‖ not a proscription.
183
 Moreover, because 
the NIH‘s policy is limited to the federal funding of research in-
volving embryos, it does not stop or attempt to regulate research 
and development by private parties.
184
 
Despite its limited authority, the NIH‘s policy against funding 
HGM has likely served as a deterrent based on the costs and 
complexities associated with traditional HGM techniques, the as-
sociated risks, and poor public perception.
185
 However, all of this 
has changed in light of the development of CRISPR technology. 
Given that CRISPR is easy to use and highly affordable, ―it would 
not take an outrageous amount of money to try to do it private-
ly.‖
186
 Thus, the NIH‘s moratorium is ―unlikely to be much of a de-
terrent,‖ since its policy is limited to research funded by the fed-
eral government and D-W only prevents federal funding of 
research that destroys an embryo.
187
 
 
 178. See REPRODUCTION AND RESPONSIBILITY, supra note 121, at 114 (calling the NIH a 
―major funder of human gene-transfer research and the basic science that underpins it‖). 
 179. Id. at 111. 
 180. Id. 
 181. See id. at 114 (noting that the NIH may also accept and review ―protocols from 
researchers who voluntarily submit them, regardless of the funding source‖). 
 182. See id. at 198. 
 183. FRANKEL & CHAPMAN, supra note 19, at 45–46. 
 184. See John A. Robertson, Procreative Liberty in the Era of Genomics, 29 AM. J.L. & 
MED. 439, 483 (2003) (stating the Congressional ban on funding for embryo research left 
―the matter in the hands of the private sector‖). 
 185. See supra Part II. 
 186. GMO SAPIENS, supra note 1, at 96. 
 187. Id. 
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B. Recommended Regulatory Framework 
While the current regulatory scheme does not attempt to strike 
a balance between the safety concerns and moral imperatives of 
HGM, preexisting laws governing other types of genetic modifica-
tions indicate Congress acknowledges that both safety and ethics 
are important considerations in this area. For example, the exist-
ence of regulation in somatic gene therapy suggests a general in-
tention by Congress to oversee and ensure the safety of research 
involving genetic engineering in human beings. Similarly, the 
federal prohibition on funding research that destroys human em-
bryos likely indicates a Congressional intention to impose moral 
restrictions on scientific experiments. Given that Congress has 
already adopted laws to address these issues separately, it would 
not be a huge leap to pass a law that allows for the consideration 
of both safety and morality when it comes to the development and 
use of HGM technologies. 
Congress could pass legislation either expanding the scope of 
FDA authority to encompass HGM technologies or create a new 
regulatory agency. Given the American legal landscape and the 
fact that CRISPR is still so new, it is unlikely that Congress 
would be able to get past the politicization that goes along with 
embryonic research and development to create a new agency. 
Thus, it would be more realistic to expand the scope of FDA au-
thority. Doing so would provide a mechanism for oversight with-
out having to create a new regulatory agency. The FDA already 
has vast experience in regulating the safety and efficacy of clini-
cal research and development; thus, its skills would arguably 
transfer well to the area of HGM. 
One concern with expanding the FDA‘s jurisdiction to include 
CRISPR germline-editing technologies is that ―it might be neces-
sary for the FDA to construe an embryo that might be transferred 
into a uterus as a ‗drug,‘ ‗biological product,‘ or ‗device.‘‖
188
 Howev-
er, this will not likely be the case. According to the FDA, gene 
transfer technology is ―any exposure to gene therapy products . . . 
by any route of administration‖ and gene therapy products are 
―[a]ll products that mediate their effects by transcription and/or 
translation of transferred genetic material and/or by integrating 
into the host genome and that are administered as nucleic acids, 
 
 188. REPRODUCTION AND RESPONSIBILITY, supra note 121, at 61.  
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viruses, or genetically engineered microorganisms.‖
189
 ―CRISPR-
Cas systems certainly fall under this broad purview, as they are 
virally delivered, genomically stored, and mediate their effects via 
transcriptional machinery.‖
190
 
The current regulatory system has several advantages—it of-
fers scientists the freedom to develop new and improved biotech-
nologies, promotes the safety and efficacy of products, and ―pro-
vides an extensive system of protections for human subjects 
participating in clinical trials.‖
191
 However, there is no positive 
authority that empowers the federal government to consider the 
safety of yet-to-be-conceived future generations who may be inad-
vertently affected by HGM.
192
 Nor does the current system provide 
a means for addressing problems related to immature safety 
mechanisms, unintended multigenerational side effects, the eth-
ics of embryonic experimentation, and equal access to CRISPR 
germline-editing technologies.
193
 
Thus, a model regulatory framework is one that combats the 
four primary issues articulated by this comment—(1) the rein-
forcement of social stigmas and exacerbation of inequalities, (2) 
economic pressures and consumer demands, (3) positive eugenics, 
and (4) human embryonic experimentation—and permits the use 
of CRISPR technology in HGM only where such use either avoids 
or outweighs these social and ethical concerns. 
This section argues that the United States should adopt the 
framework laid out by Niklaus H. Evitt, Shamik Mascharak, and 
Russ B. Altman because their proposed regulatory framework 
meets the above-stated ethical criteria. Evitt, Mascharak, and 
Altman propose a model regulatory framework for research, clini-
cal development, and distribution of CRISPR germline-editing 
technology that utilizes existing regulatory bodies, but calls for 
heightened scrutiny at each phase.
194
 This section expounds on 
their proposed regulatory framework, but draws from other 
sources as well. 
 
 189. U.S. FOOD & DRUG ASS‘N, GUIDANCE FOR INDUSTRY: GENE THERAPY CLINICAL 
TRIALS—OBSERVING SUBJECTS FOR DELAYED ADVERSE EVENTS 2, 4 (2006). 
 190. Evitt et al., supra note 97, at 27. 
 191. REPRODUCTION AND RESPONSIBILITY, supra note 121, at 170. 
 192. Id. at 169. 
 193. See Evitt et al., supra note 97, at 28. 
 194. See id. at 28–29. 
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1.  Research Phase 
Although CRISPR must overcome several technical and ethical 
obstacles before it can be used safely for HGM purposes, the 
technology is developing at an unprecedented rate, and is poised 
to shock an unsuspecting society if not carefully considered and 
properly regulated.
195
 In the interest of preparing the public for 
such developments, a system of oversight should be put in place 
at the national level and should regulate HGM in both the public 
and private sector.
196
 
Regulating HGM should occur in two ways. First, there should 
be an ethical threshold test that all proposed studies must pass in 
order to be approved for research. Second, specialized oversight 
committees (―SOCs‖) that are composed of well-trained, disinter-
ested members should be responsible for rendering such approval. 
Researchers also must meet certain ethical training requirements 
for approval of their respective study. 
a.  Ethical Threshold Test 
Given the ethical and safety concerns posed by CRISPR tech-
nology in HGM, research and clinical development should not 
proceed unless (1) germline intervention is the only way to pro-
duce healthy offspring or (2) the benefits of the proposed therapy 
significantly outweigh the embryo loss and other associated 
risks.
197
 In either situation, any HGM study that lacks a validated 
reversal mechanism should be prohibited.
198
 
There are two basic scenarios in which the use of CRISPR in 
HGM should be permissible. First is where germline intervention 
is the only way to produce healthy offspring. This situation would 
 
 195. Id. at 25 (indicating ―an urgent need for practical paths for the evaluation of these 
capabilities‖). 
 196. FRANKEL & CHAPMAN, supra note 19, at 51. 
 197. Evitt et al., supra note 97, at 26. 
 198. Id. There is currently no way to reverse the effects of harmful germline modifica-
tions. Id. at 26. Thus, a proven reversal strategy must be developed for any HGM study to 
move forward. Prospects such as the gene drive strategy, a chemically induced secondary 
gene program, are still theoretical. Kevin M. Esvelt et al., Concerning RNA-Guided Gene 
Drives for the Alternation of Wild Populations, ELIFE 1, 10 (2014). In theory, the gene 
drive overwrite strategy can ―precisely reverse the original therapeutic edit.‖ Evitt et al., 
supra note 97, at 26 (suggesting ―chemical induction of reversal mechanisms must be or-
thogonal to natural biochemistry so that removal of original gene edits is not accidentally 
triggered‖). 
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apply where one parent is homozygous for a dominant disorder or 
where both parents are homozygous for a recessive disorder.
199
 In 
these situations, all embryos would be affected by the disorder 
and would not benefit from screening and selection procedures.
200
 
Thus, HGM would be morally justifiable because there are few al-
ternatives for the parents to avoid passing on defective genes to 
their biological offspring.
201
 
Second, the use of CRISPR technology in HGM should be per-
missible only where the benefits of the proposed therapy signifi-
cantly outweigh the embryo loss and other associated risks. This 
situation involves performing a cost-benefit analysis of the pro-
posed therapy with the primary goal of minimizing embryonic de-
struction throughout the research process.
202
 This would provide 
an ethical use of germline editing for diseases with a large poten-
tial patient population because, in the end, fewer embryos would 
be destroyed—thus addressing the fourth concern of CRISPR 
germline-editing technology: the destruction of human embryos in 
embryonic experimentation.
203
 Even if parents could avoid passing 
on defective genes to their child via screening and selection pro-
cedures, embryos carrying genetic disorders are ultimately de-
stroyed every time parents conduct prenatal genetic diagnosis 
during an in vitro fertilization cycle.
204
 In other words, where 
there is a large patient population, in vitro genetic profiling and 
screening is sure to result in significant embryo loss. If the popu-
lation-wide embryo loss in prenatal genetic diagnosis is likely to 
surpass the embryo loss during CRISPR research, then develop-
ing a CRISPR germline-editing therapy is morally justified be-
cause doing so would minimize the net embryo loss.
205
 In either 
situation, ―there must be a compelling reason for doing the gene 
editing in human embryos‖ rather than using the less ethically 
 
 199. Lander, supra note 27, at 6; see also FRANKEL & CHAPMAN, supra note 19, at 62 
(defining homozygosity as the ―state in which the two alleles of a gene at a specific locus 
are identical‖). 
 200. See Lander, supra note 27, at 6. 
 201. See FRANKEL & CHAPMAN, supra note 19, at 13. 
 202. See Evitt et al., supra note 97, at 26 (maintaining that ―embryos bear an interme-
diate moral status between nonhuman life and a fetus‖). 
 203. Id. While the destruction of no human embryos would be an ideal result, one must 
take into account that embryonic destruction already occurs in genetic screening and em-
bryo selection procedures. Therefore, it is important to keep in mind that this conclusion is 
based upon a comparative analysis to not only the current regulatory scheme, but also to 
current medical practices and procedures. 
 204. Id. 
 205. Id. 
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challenging method involving human cells cultured in a dish and 
limited to the laboratory setting.
206
 
b. SOC Approval 
If and when a proposed therapy passes either threshold test by 
showing necessity or benefit, researchers should be required to 
obtain approval from local SOCs for any studies involving genetic 
modification in human stem cells and embryos. These committees 
will supervise the proposed study if it passes the other regulatory 
guidelines.
207
 
In the United Kingdom, the Human Fertilization and Embryol-
ogy Authority (―HFEA‖) regulates all experiments involving hu-
man embryos by requiring researchers to obtain a license in order 
to perform any such experiment.
208
 Researchers are not even per-
mitted to apply for a license, unless and until they have sought 
and been granted ―research ethics approval by a properly consti-
tuted ethics committee.‖
209
 In the United States, institutional re-
view boards (IRBs) serve a similar function; however, their regu-
latory focus is on biomedical research involving early-stage 
human embryos.
210
 Because embryos are not considered ―human 
subjects‖ and, consequently, not afforded the same protections 
under the Common Rule (e.g., informed consent), research involv-
ing CRISPR germline-editing technologies may fall outside of IRB 
authority.
211
 In addition, IRBs are not required to consider long-
term social ramifications when deciding to approve research.
212
 
Given these inadequacies in existing regulatory oversight, 
SOCs should be created to oversee the ethical development of 
 
 206. GMO SAPIENS, supra note 1, at 239. 
 207. See Evitt et al., supra note 97, at 26–27; see also GMO SAPIENS, supra note 1, at 
240 (indicating that ―[m]ost U.S. universities already have committees that oversee stem 
cell and embryo research (often called ―SCRO‖ for stem cell research and oversight) . . . 
[and] these same committees could review applications from researchers wanting to make‖ 
genetically modified human embryos). 
 208. Legislative Guide to Licensing, HUMAN FERTILIZATION & EMBRYOLOGY AUTH. 1, 
http://www.hfea.gov.uk/docs/Legislative_Guide_to_Licensing.PDF (last visited Dec. 16, 
2016). 
 209. Id. at 10. 
 210. See REPRODUCTION AND RESPONSIBILITY, supra note 121, at 201. 
 211. See id. at 134. 
 212. See id. at 201 (indicating IRBs generally do not apply special rules for research 
involving early-stage human embryos or consider the ―moral questions relating explicitly 
to the destruction of developing human life‖). 
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HGM technologies and should have responsibilities that extend 
beyond the Common Rule‘s ―human subject‖ protection.
213
 
SOCs should be composed of disinterested, specialized, and di-
verse stakeholders.
214
 To reduce the risk that these committees 
will simply ―rubber stamp‖ research proposals,
215
 there should be 
national membership guidelines that require the committees to 
meet specific composition requirements.
216
 Similarly, researchers 
proposing to conduct research on the genetic modification of hu-
man germ cells or embryos should also be required to have a cer-
tain level of specialized training, particularly in the area of bio-
ethics, to submit a research proposal.
217
 HGM raises complicated 
bioethical issues, and requiring bioethical training ―would serve 
to provide a strong educational component.‖
218
 For example, 
CRISPR human genetic modification research could substantially 
increase the research demand for human eggs.
219
 Scientists should 
be equipped to handle the ethical considerations related to sourc-
ing human oocytes and prepared to recognize with certainty 
―what might be ethical or unethical in this area of research.‖
220
 
SOC power and authority should be standardized by federal 
mandate in order to grant the appropriate level of oversight and 
ensure consistent policy at a national level.
221
 Granting such au-
thority to specialized committees will not only reduce the risk of 
unethical research and development, but will also put the power 
of scientific research and development back in the hands of scien-
tists, who are best suited to make such decisions—rather than 
giving unspecialized regulatory agencies and knee-jerk politicians 
the authority to make unfounded assessments. 
Before granting approval, SOCs should evaluate whether re-
searchers have demonstrated proof of concept by looking at 
whether the proposed study has been used in applying gene edits 
 
 213. See Evitt et al., supra note 97, at 27. 
 214. See id. (―Local oversight committees should be composed of researchers, physi-
cians, ethicists, and community members with nonconflicting interests, much like stem 
cell research oversight (SCRO) committees.‖). 
 215. See GMO SAPIENS, supra note 1, at 240 (suggesting this is a realistic concern for 
some university committees). 
 216. Evitt et al., supra note 97, at 27. 
 217. GMO SAPIENS, supra note 1, at 240. 
 218. Id. 
 219. Id. 
 220. Id. 
 221. Evitt et al., supra note 97, at 27. 
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to appropriate ―somatic cells and multigenerational animal mod-
els.‖
222
 Committees should also question the ethical nature of the 
proposed studies and the necessity of using human embryos to 
perform the associated experiments.
223
 If studies pose significant 
ethical burdens, have the potential for abuse, or can be conducted 
without the use of human embryos,
224
 then the committees should 
deny them.  
SOC approval should be a prerequisite to FDA approval, which 
must be obtained for any research study to advance to the clinical 
development phase. 
2.  Clinical Development 
Upon receiving approval from appropriate SOCs, research pro-
posals should be subject to FDA review and approval before clini-
cal use.
225
 As explained previously, ―[p]rior FDA policies concern-
ing gene transfer therapies readily port over to [CRISPR 
germline-editing therapies].‖
226
 
Clinical trials test potential treatments in human subjects to 
determine whether they are appropriate for widespread use in 
the general population.
227
 Potential treatments include drugs, 
medical devices, and biologics such as gene therapy.
228
 There are 
four phases of clinical trials, each of which is designed to answer 
a different research question.
229
 
Phase I: Researchers test a new drug or treatment in a small 
group of people for the first time to evaluate its safety, determine a 
safe dosage range, and identify side effects. 
Phase II: The drug or treatment is given to a larger group of peo-
ple to see if it is effective and to further evaluate its safety. 
Phase III: The drug or treatment is given to large groups of peo-
ple to confirm its effectiveness, monitor side effects, compare it to 
 
 222. Id. at 26. 
 223. GMO SAPIENS, supra note 1, at 240. 
 224. For example, if the experiment can be performed just as well with cultured human 
cells in a petri dish, it should be rejected. 
 225. Evitt et al., supra note 97, at 27. 
 226. Id.; see also supra note 190 and accompanying text.  
 227. Conducting Clinical Trials, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Dru 
gs/DevelopmentApprovalProcess/ConductingClinicalTrials/default.htm (last visited Dec. 
16, 2016). 
 228. Id. 
 229. See FAQ ClinicalTrials.gov—Clinical Trial Phases, U.S. NAT‘L LIBRARY OF MED., 
https://www.nlm.nih.gov/services/ctphases.html (last visited Dec. 16, 2016). 
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commonly used treatments, and collect information that will allow 
the drug or treatment to be used safely. 
Phase IV: Studies are done after the drug or treatment has been 
marketed to gather information on the drug‘s effect in various popu-
lations and any side effects associated with long-term use.
230
 
Prior to Phase I clinical trials, ―care should be taken to receive 
parental informed consent.‖
231
 Although HGM arguably leads to 
―generations of nonconsent,‖ parents regularly make medical de-
cisions on behalf of children.
232
 This notion, combined with the 
fact that subsequent nonexistent beings (i.e., generations that 
have yet to be conceived) arguably have no recognizable consent 
rights, may make consent a non-issue all together.
233
 Consent may 
also be a non-issue in this arena because it does not function to 
―permit what would otherwise be a violation of autonomy.‖
234
 
Even if it made sense to talk about the subsequent consent of future 
persons, lack of consent would not provide a justification for a blan-
ket prohibition on germ-line genetic engineering. In fact, it provides 
little useful guidance. We are typically in no position to make rea-
sonable predictions about what people in future generations will ap-
prove of and hence what they will consent to. The problem is that the 
cultural context may change over a number of generations. In addi-
tion, we are not able to predict what technologies will be available in 
the future and how they will shape values. Finally, we do not know 
how the moral and political debates that influence policy will turn 
out.
235
 
It is a ―conceptual confusion‖ to discuss the consent of future 
persons to present practices.
236
 Thus, well-informed parental con-
sent should suffice for HGM clinical trials. 
There should, however, be a greater standard of informed con-
sent for all future parents participating in HGM clinical trials 
that emphasizes the possibility of unanticipated latent side ef-
 
 230. Id. 
 231. Evitt et al., supra note 97, at 27. 
 232. Id. 
 233. Id.; see also Ronald Munson & Lawrence H. Davis, Germ-line Gene Therapy and 
the Medical Imperative, 2 KENNEDY INST. ETHICS J. 137, 143, 151–52 (1992) (arguing there 
is no moral objection to germline therapy too great to overcome and also suggesting the 
survival of the human race may depend on germline genetic manipulations one day). 
 234. Martin Gunderson, Genetic Engineering and the Consent of Future Persons, 18 J. 
EVOLUTION & TECH. 86, 91 (2008) (agreeing that consent is a non-issue, but ―not because it 
is impossible to thwart the autonomy of non-existing persons‖). 
 235. Id. at 88. 
 236. Id. at 86. 
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fects.
237
 While it may be impossible to inform a patient about un-
anticipated side effects (because, at that point, would they not be 
anticipated?), researchers should do their best to stress the un-
certainty that goes with HGM and ensure patients understand 
that the realm of possible outcomes is vast and similarly uncer-
tain. Instead of a one-size-fits-all warning label telling patients 
nothing more than ―expect the unexpected,‖ scientists should in-
struct patients to consider the myriad of personal attributes in-
fluenced by genetics—including physical features, medical health, 
mental health and stability, moral character and decision mak-
ing, etc. In the end, patients should not only understand the an-
ticipated consequences of their specific procedure, but they should 
also have a general understanding of human genetics and the ac-
companying risks and uncertainties to be considered ―informed‖ 
enough to give consent. 
During Phase I–III clinical trials, CRISPR germline-editing 
technologies should be made readily available to patients from all 
socio-economic backgrounds as soon as possible, while also con-
clusively demonstrating safety and efficacy.
238
 While multigenera-
tional trials would be the best way to conclusively demonstrate 
safe outcomes and obtain reproducible data over generations, 
―multigenerational Phase I–III trials may be impractical.‖
239
 In-
stead, positive long-term outcomes could be confirmed during 
mandatory multigenerational Phase IV trials while also mitigat-
ing unnecessary time burdens during the development phase.
240
 
3. Distribution 
Following FDA approval and commercialization, CRISPR 
germline-editing technology should be made available to persons 
of all socioeconomic backgrounds at IVF clinics across the coun-
try. This would not only eliminate inequality concerns, it would 
 
 237. Evitt et al., supra note 97, at 27. 
 238. Id. 
 239. Id. There are several reasons multigenerational HGM trials might be impractical. 
One reason could be how the sheer time and money it would take to sponsor a trial span-
ning the course of several generations of human beings would not likely be productive nor 
forthcoming. Or, multigenerational trials might be impractical because there is no cog-
nizable point at which scientists could say with certainty that the product or procedure 
was either a failure or success due to the possibility of latency, the influence of environ-
mental factors, and the infinite number of possible outcomes that would vary based on the 
genetic makeup of the mother and father. 
 240. Id. 
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also combat issues related to increased social stigma and econom-
ic pressure. In order to achieve this goal, there should be legisla-
tive mechanisms in place to ensure best practices are adopted by 
healthcare professionals and to safeguard ―those who cannot or 
choose not to use this technology.‖
241
 
―For example, insurance companies should not be permitted to 
raise deductibles of deaf parents who choose to conceive a deaf 
child; regardless of the morality of this decision, it is still legally 
viewed as a matter of parental autonomy.‖
242
 If not properly regu-
lated, private insurance companies might try to ―punish‖ parents 
who forego HGM and, as a result, are likely to have a child that 
will require a more expensive procedure, such as cochlear implant 
surgery, which can cost between $50,000 and $100,000 with the 
required follow up.
243
 
Further, access to useful germline-editing technologies should 
also be made reasonably available to parents of lower socioeco-
nomic status.
244
 To do otherwise would ―add inherited advantages 
to all the benefits of nurture and education already enjoyed by 
the affluent,‖ and create yet another barrier between the ―haves‖ 
and ―have-nots‖ of society.
245
 However, regulators should be care-
ful not to do so in a manner that inappropriately encourages the 
use of HGM technology. 
Children with physical and mental disabilities require more 
care and attention in the classroom than the average student. For 
example, ―it costs at least ten times as much, on an annual basis, 
to educate a deaf child in a residential school for the deaf, than it 
does to educate that same student in a mainstream classroom.‖
246
 
Similarly, educating children with other impairments and disabil-
ities—such as intellectual disabilities and visual, speech, or lan-
 
 241. Id. at 27–28. 
 242. Id. at 28; see also FRANKEL & CHAPMAN, supra note 19, at 37 (―At a minimum, 
most private insurers are likely to delay agreeing to reimburse policy holders for these ge-
netic services until their efficacy and safety are clearly demonstrated.‖). 
 243. Adam B. Zimmerman, Do You Hear the People Sing? Balancing Parental Authori-
ty and a Child’s Right to Thrive: The Cochlear Implant Debate, 5 J. HEALTH & BIOMED. L. 
309, 318 (2009). 
 244. See FRANKEL & CHAPMAN, supra note 19, at 36 (suggesting that major changes in 
the U.S. health care system are required in order to prevent a lack of equity in access to 
HGM products and services). 
 245. Id. at 37. 
 246. Zimmerman, supra note 243, at 319. 
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guage impairments—also costs considerably more in terms of the 
services special education children need and receive.
247
 While the 
Individuals with Disabilities Education Act (―IDEA‖) covers only 
a small share of the total expenditures on special education, fed-
eral funding on special education through IDEA was around $12 
billion in 2010.
248
  
If CRISPR technology reaches a point at which ―correcting‖ 
such disabilities would be cheaper for the federal government 
than funding special education programs, it may become tempt-
ing for legislators to inappropriately incentivize HGM procedures. 
However, this must be fervently avoided. Under no circumstance 
should the government attempt to further its own fiscal agenda 
by incentivizing HGM procedures, by taxing the lack thereof, or 
by any other means. 
To be sure, legislators and regulators will need to strike a deli-
cate balance between making HGM widely available and protect-
ing parental autonomy. But given CRISPR‘s simplicity, afforda-
bility, and widespread use, providing access to those in need of 
CRISPR human germline modification technology, but perhaps 
cannot afford to finance the procedure on their own, should be a 
feasible policy option. 
CONCLUSION 
The development of CRISPR technology has prompted much 
debate about the ethical dilemmas presented by its use in the 
HGM setting, but little attention has been given to the issue of 
how germline therapies would be developed in a responsible and 
practicable manner. As discussed throughout, CRISPR technology 
is both revolutionary and perilous. However, the very characteris-
tics that make CRISPR such a groundbreaking advancement are 
also the features that warrant careful consideration moving for-
ward. The proposed regulatory framework would meet the ethical 
and technical demands posed by using CRISPR technology for 
HGM purposes.  
 
 247. See Laudan Aron & Pamela Loprest, Disability and the Education System, 22 
FUTURE CHILD. 97, 99, 109 (2012). 
 248. Id. at 109. 
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Taken as a whole, this comment addresses concerns about mul-
ti-generational risks, underdeveloped safety mechanisms, bioeth-
ical dilemmas, and social consequences such as eugenics, inequal-
ity, economic pressures, and the like. In doing so, it seeks to 
promote the ongoing conversation and open the door to further 
legal analysis and debate, which must occur before society is 
ready to face the potentially powerful repercussions of modifying 
the human germline. 
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